Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
2.715
-0.035 (-1.27%)
Dec 3, 2024, 11:44 AM EST - Market open
Sutro Biopharma Employees
Sutro Biopharma had 302 employees as of December 31, 2023. The number of employees increased by 24 or 8.63% compared to the previous year.
Employees
302
Change (1Y)
24
Growth (1Y)
8.63%
Revenue / Employee
$532,964
Profits / Employee
-$410,440
Market Cap
223.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SOPHiA GENETICS | 430 |
ADC Therapeutics | 274 |
Utah Medical Products | 190 |
Solid Biosciences | 88 |
XBiotech | 82 |
Sera Prognostics | 57 |
Orchestra BioMed Holdings | 56 |
Compass Therapeutics | 32 |
STRO News
- 19 days ago - Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - GlobeNewsWire
- 4 weeks ago - Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - GlobeNewsWire
- 7 weeks ago - Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewsWire
- 2 months ago - Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
- 2 months ago - Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - GlobeNewsWire
- 2 months ago - Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 - GlobeNewsWire